Rating Change
Guggenheim reiterated its Buy rating on Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on August 13, 2026.
reiterateNASDAQ:UNCY
Guggenheim Reiterates Buy Rating on Unicycive Therapeutics, Inc. (UNCY)
Guggenheim reiterated its Buy rating on Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on August 13, 2026.
At publication ·
What changed
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) · reiterate
- Firm
- Guggenheim
- Rating
- Buy to Buy
- Price at event
- $5.40
- Market capitalization
- $113.3M
At a glance
Key takeaways
- Guggenheim reiterated a Buy rating on Unicycive Therapeutics (UNCY) on August 13, 2026, with the stock trading at $5.40 and a market capitalization of $113.3 million.
Market Context
Unicycive Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $5.40 with a market capitalization of $113.3M.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Unicycive Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Unicycive Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 13, 2026 | Guggenheim | Buy | N/A |
| Aug 13, 2026 | B. Riley Securities | Buy | N/A |
| Jul 01, 2026 | Benchmark | Speculative Buy | N/A |
| Jul 01, 2026 | Noble Capital Markets | Outperform | N/A |
| Jun 30, 2026 | B. Riley Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View UNCY Stock Page
Frequently Asked Questions
What does the Buy rating mean for UNCY?
A rating of Buy from Guggenheim reflects the analyst's outlook on Unicycive Therapeutics, Inc. (NASDAQ:UNCY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the UNCY forecast page.